Achim Aigner

11.8k total citations · 2 hit papers
204 papers, 9.2k citations indexed

About

Achim Aigner is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Achim Aigner has authored 204 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Molecular Biology, 40 papers in Cancer Research and 36 papers in Oncology. Recurrent topics in Achim Aigner's work include RNA Interference and Gene Delivery (82 papers), Advanced biosensing and bioanalysis techniques (58 papers) and MicroRNA in disease regulation (30 papers). Achim Aigner is often cited by papers focused on RNA Interference and Gene Delivery (82 papers), Advanced biosensing and bioanalysis techniques (58 papers) and MicroRNA in disease regulation (30 papers). Achim Aigner collaborates with scholars based in Germany, United States and Poland. Achim Aigner's co-authors include Frank Czubayko, Sabrina Höbel, Anton Wellstein, Anastasia Malek, Maik Friedrich, Udo Bakowsky, Thomas Kissel, Alexander Ewe, Ulrike Weirauch and Roland K. Hartmann and has published in prestigious journals such as Journal of Biological Chemistry, Angewandte Chemie International Edition and Nature Medicine.

In The Last Decade

Achim Aigner

200 papers receiving 9.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo

2004 560 citations Achim Aigner et al. profile →
Therapeutic siRNA: State-of-the-Art and Future Perspectives

2022 256 citations Achim Aigner et al. profile →

Peers

Countries citing papers authored by Achim Aigner

Since Specialization

Citations

This map shows the geographic impact of Achim Aigner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Achim Aigner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Achim Aigner more than expected).

Fields of papers citing papers by Achim Aigner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Achim Aigner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Achim Aigner. The network helps show where Achim Aigner may publish in the future.

Co-authorship network of co-authors of Achim Aigner

This figure shows the co-authorship network connecting the top 25 collaborators of Achim Aigner. A scholar is included among the top collaborators of Achim Aigner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Achim Aigner. Achim Aigner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The MicroRNA miR-454 and the mediator complex component MED12 are regulators of the androgen receptor pathway in prostate cancer 2025 ·Scientific Reports ·(unknown), Martin Hart, (unknown), (unknown), Achim Aigner, (unknown), Florian Handle, Stefanie Rheinheimer, Ulrike Fischer, Uta‐Dorothee Immel, Verena Lieb, Eckart Meese, Zoran Čulig, Bernd Wullich, Helge Täubert, Sven Wach	1
2	RNA drugs and nonviral nanocarriers in oncology – present status and emerging concepts 2025 ·Biochemical and Biophysical Research Communications ·Achim Aigner	1
3	Analysis of Polymer/siRNA Nanoparticle Efficacy and Biocompatibility in 3D Air–Liquid Interface Culture Compared to 2D Cell Culture 2025 ·Pharmaceutics ·(unknown), Martin Krueger, Alexander Ewe, Achim Aigner	1
4	MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer 2024 ·Endocrinology ·(unknown), (unknown), Elisa Morales, (unknown), Martin Puhr, (unknown), Sven Wach, (unknown), Achim Aigner, Iris E. Eder, Florian Handle, Zoran Čulig	4
5	A new human autologous hepatocyte/macrophage co-culture system that mimics drug-induced liver injury–like inflammation 2024 ·Archives of Toxicology ·(unknown), (unknown), (unknown), (unknown), (unknown), Sabrina Ehnert, (unknown), (unknown), Achim Aigner, Susanne Schiffmann, Andreas K. Nüssler, Daniel Seehofer, Georg Damm	2
6	Comparison of tyrosine-modified low molecular weight branched and linear polyethylenimines for siRNA delivery 2022 ·Nanotoxicology ·(unknown), Sylwia Michlewska, (unknown), Alexander Ewe, Achim Aigner, Maria Bryszewska, Максим Йонов	3
7	STAT3 Enhances Sensitivity of Glioblastoma to Drug-Induced Autophagy-Dependent Cell Death 2022 ·Cancers ·(unknown), Benedikt Linder, Ulrike Weirauch, Bryan W. Day, Brett W. Stringer, Christel Herold‐Mende, Achim Aigner, Knut Krohn, Donat Kögel	10
8	Unmodified and tyrosine-modified polyethylenimines as potential carriers for siRNA: Biophysical characterization and toxicity 2022 ·International Journal of Pharmaceutics ·(unknown), Sylwia Michlewska, (unknown), Alexander Ewe, (unknown), Achim Aigner, Maria Bryszewska, Максим Йонов	18
9	Experimental in vitro, ex vivo and in vivo models in prostate cancer research 2022 ·Nature Reviews Urology ·Verena Sailer, Gunhild von Amsberg, Stefan Duensing, Jutta Kirfel, Verena Lieb, Eric Metzger, Anne Offermann, Klaus Pantel, (unknown), Helge Täubert, Sven Wach, Sven Perner, Stefan Werner, Achim Aigner	31
10	Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers 2021 ·Cancers ·Hong‐Gui Xu, Viktor Reshetnikov, (unknown), (unknown), Leoni A. Kunz‐Schughart, Christina Janko, Rainer Tietze, Christoph Alexiou, (unknown), Achim Aigner, Wenjie Gong, Michael Schmitt, Leopold Sellner, Steffen Daum, (unknown), Andriy Mokhir	10
11	Tetraspanin 5 (TSPAN5), a Novel Gatekeeper of the Tumor Suppressor DLC1 and Myocardin-Related Transcription Factors (MRTFs), Controls HCC Growth and Senescence 2021 ·Cancers ·(unknown), (unknown), (unknown), (unknown), Dietmar E. Martin, Kerstin C. Maier, K Huebner, Regine Schneider‐Stock, Stephan Singer, Kerstin Hölzer, Dagmar Fischer, Silvia Ribback, Bernhard Liebl, Thomas Gudermann, Achim Aigner, Susanne Muehlich	10
12	Glioblastoma Tissue Slice Tandem-Cultures for Quantitative Evaluation of Inhibitory Effects on Invasion and Growth 2020 ·Cancers ·(unknown), (unknown), (unknown), (unknown), Donat Kögel, Achim Temme, Ute Krügel, Heike Franke, Achim Aigner	6
13	Restoration of MARCK enhances chemosensitivity in cancer 2020 ·Journal of Cancer Research and Clinical Oncology ·(unknown), Thomas Büch, Nicole Urban, Ulrike Weirauch, Katrin Schierle, Achim Aigner, Michael Schaefer, Hermann Kalwa	12
14	Mono- and Polyassociation Processes of Pentavalent Biotinylated PEI Glycopolymers for the Fabrication of Biohybrid Structures with Targeting Properties 2019 ·Biomacromolecules ·(unknown), Susanne Boye, (unknown), Sabrina Höbel, Katarzyna Woźniak, Sílvia Moreno, Andreas Janke, Albena Lederer, Achim Aigner, Achim Temme, Brigitte Voit, Dietmar Appelhans	7
15	Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model 2019 ·Cancers ·Benedikt Linder, Ulrike Weirauch, Alexander Ewe, Anja Uhmann, Volker Seifert, Michel Mittelbronn, Patrick N. Harter, Achim Aigner, Donat Kögel	26
16	Cell-type specific and non-redundant anti-proliferative effects of shRNA-mediated Galpha12- and Galpha13 knockdown in lung cancer cell lines 2014 ·Advances in Bioscience and Biotechnology ·Thomas Büch, Marius Grzelinski, Olaf Pinkenburg, Thomas Gudermann, Achim Aigner	1
17	MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma 2011 ·Cancer Research ·(unknown), Ulrike Weirauch, Maren Thomas, Arnold Grünweller, Roland K. Hartmann, Achim Aigner	331
18	Critical Role of Gα12 and Gα13 for Human Small Cell Lung Cancer Cell Proliferation In vitro and Tumor Growth In vivo 2010 ·Clinical Cancer Research ·Marius Grzelinski, Olaf Pinkenburg, Thomas Büch, Maike Gold, (unknown), Hermann Kalwa, Thomas Gudermann, Achim Aigner	31
19	Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung 2010 ·European Journal of Pharmaceutics and Biopharmaceutics ·(unknown), Jens Lipka, Anastasia Malek, (unknown), Wolfgang G. Kreyling, Achim Aigner	144
20	N‐アセチル‐L‐システインの水溶液の安定性 1994 ·Achim Aigner, A. Wahl, (unknown), (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact